# International Cannabis Policies and Their Association with Cannabis Use, Cannabis Use Disorder, and Other Psychiatric Disorders > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/international-cannabis-policies-cannabis-use-disorder-impact/ > **Published:** 2026-06-19T17:33:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:25-04:00 > **Clinical Summary:** Explore how international cannabis policies influence cannabis use and cannabis use disorder rates, with insights on psychiatric disorder associations. --- Table of Contents - [Clinical Takeaway](#Clinical_Takeaway) - [#32 International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders.](#32_International_cannabis_policies_and_their_association_with_cannabis_use_cannabis_use_disorder_and_other_psychiatric_disorders) - [What This Study Teaches Us](#What_This_Study_Teaches_Us) - [Why This Matters Clinically](#Why_This_Matters_Clinically) - [Study Snapshot](#Study_Snapshot) - [Where This Paper Deserves Skepticism](#Where_This_Paper_Deserves_Skepticism) - [Dr. Caplan’s Take](#Dr_Caplans_Take) - [Clinical Bottom Line](#Clinical_Bottom_Line) - [Related](#Related) #### Clinical Takeaway Legalizing cannabis for non-medical use in places like Canada and the United States has been linked to more adults using cannabis, higher rates of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and increased product potency. The research does not show a consistent connection between policy changes and broader psychiatric disorder rates. These findings suggest that commercialized legal markets expand access and use among adults, with measurable clinical consequences worth monitoring. ### #32 International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders. **Citation:** Freeman Tom P et al. *International cannabis policies and their association with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and other psychiatric disorders.* The lancet. Psychiatry. 2026. PMID: 42309107. **Study type:** Journal Article, Review  |  **Topic area:** Psychosis  |  **CED Score:** 10 Design: 0 Journal: 4 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 **Abstract:** Cannabis policies vary from strict prohibition to commercialised legalisation and are rapidly evolving worldwide. Here, we reviewed evidence for associations between international cannabis policy changes from 2000-25 and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), cannabis use disorder, and other psychiatric disorders. Commercialised legal markets for non-medical use in Canada and the USA were associated with increased prevalence of cannabis use and cannabis use disorder in adults and increases in cannabis potency since legalisation. There was no consistent evidence for associations between policy change and the prevalence or incidence of psychotic disorders. Commercialised legalisation was associated with an increase in hospital admissions for psychosis, and for psychotic disorders comorbid with cannabis use disorder. Poorly regulated legal access to [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), in the absence of efficacy and safety data, could increase risk of harm. Policies that limit commercialisation, such as strictly regulated legalisation of medical or non-medical supply, were not as strongly associated with cannabis use or psychiatric disorders, but long-term evaluation is needed. There was little evidence that decriminalisation of non-medical cannabis in Europe, Africa, Oceania, and Asia was associated with cannabis use or psychiatric disorders. ### What This Study Teaches Us Commercialized legal cannabis markets in North America have been associated with increased use, cannabis use disorder, and hospital admissions for psychosis, but decriminalization without commercialization in Europe and other regions has not shown these same associations. Strict regulation of medical or non-medical supply appears to carry less psychiatric risk than fully commercialized markets. ### Why This Matters Clinically Clinicians need to know that cannabis policy itself is a risk factor worth discussing with patients, and that the type of legalization matters. Whether a patient lives in a commercialized market versus a medically-regulated one changes the baseline risk profile for both addiction and acute psychiatric emergencies they may encounter. ### Study Snapshot **Study Design** Narrative review of evidence on cannabis policy changes and associated outcomes from 2000-2025 **Population** International populations across jurisdictions with varying cannabis policies; no single cohort described **Intervention** Cannabis policy changes categorized as prohibition, decriminalization, regulated medical legalization, or commercialized legalization **Primary Outcome** Associations between policy type and prevalence of cannabis use, cannabis use disorder, psychotic disorders, and hospital admissions **Key Result** Commercialized legalization associated with increased use disorder and psychosis hospital admissions; decriminalization not associated with increased psychiatric burden; regulated medical access had intermediate risk ### Where This Paper Deserves Skepticism This is a narrative review, not a meta-analysis, so quality assessment and publication bias are not addressed. The abstract does not specify how many studies were included, whether confounders like changing demographics or other drug policies were adjusted for, or how long-term outcomes were measured. The causal directionality remains unclear: did legalization increase use and disorder, or did higher baseline use drive legalization? Different countries’ data collection methods and definitions of cannabis use disorder may not be comparable. ### Dr. Caplan’s Take This review helps clarify that not all legalization is equal from a public health standpoint. The distinction between commercialized markets (which actively promote sales) and tightly regulated medical or non-medical programs is important clinically. I’m cautious about the psychosis findings because the abstract notes no consistent evidence for policy changes affecting psychotic disorder incidence itself, only hospital admissions, which could reflect detection bias or care-seeking patterns rather than true disease burden. Still, the data on increased use and use disorder in commercialized markets is consistent enough to warrant honest conversations with patients about market forces they’re exposed to. ### Clinical Bottom Line When counseling patients about cannabis use, the regulatory environment they live in is part of the risk calculation. Commercialized legalization carries higher risks for use disorder and acute psychiatric care; tight medical regulation or decriminalization-without-commercialization appears safer, though long-term evidence is still limited.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/42309107/)[DOI ↗](https://doi.org/10.1016/S2215-0366(26)00087-8) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20International%20cannabis%20policies%20and%20their%20association%20with%20cannabis%20use%2C%20cannabis%20use%20disorder%2C%20and%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59773)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59773)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20International%20cannabis%20policies%20and%20their%20association%20with%20cannabis%20use%2C%20cannabis%20use%20disorder%2C%20and%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59773)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) RELATED READING AT CED CLINIC Continue exploring the evidence Study links commercial cannabis markets to increased addiction – News-Medical.Net This article explores how commercial cannabis markets contribute to higher addiction rates, complementing insights on policy impacts. Read More [Cannabis Policy Changes and Adolescent Cannabis Use: Evidence from Europe – OA.mg](https://cedclinic.com/cannabis-policy-changes-and-adolescent-cannabis-use-evidence-from-europe-oa-mg/) Review evidence on how cannabis policy changes in Europe affect [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) patterns and related risks. [Explore Study](https://cedclinic.com/cannabis-policy-changes-and-adolescent-cannabis-use-evidence-from-europe-oa-mg/) [Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) A detailed comparison of cannabis use disorder with other substance use disorders, providing clinical context for policy discussions. [Learn More](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).